search returned 100 results for adalimumab, showing results 51 to 60
list reviewed; all items completed except– Pharmacy issues re:
adalimumab biosimilars and supply... this issue. Adalimumab ongoing, waiting for a response from DoH. If you
experience any issues with e... and allocated them
amongst the TC members.
o MM allocated adalimumab, certolizumab, etanercept
https://rheumatology.org.au/LinkClick.aspx?fileticket=GEQl_0kZZMs%3d&portalid=2
was
undertaken prior to the widespread availability of adalimumab biosimilars and
encourage any future... adalimumab listing as a HSD not general schedule listing
5. The APRG estimate that patients who receive adalimumab or etanercept on compassionate
grounds for non-PBS indications (uveitis or SaJIA not covered
https://rheumatology.org.au/LinkClick.aspx?fileticket=2INZ8Alrkbg%3d
re:
adalimumab biosimilars and supply of Humira as still pending response from
Pharmaceutical... and anifrolumab)
7.6 PBAC Meeting November agenda (adalimumab)
• The PBAC have released the Nov meeting agenda and the TC are invited to comment.
AbbVie have put in request for adalimumab and upadacitinib
https://rheumatology.org.au/LinkClick.aspx?fileticket=eYHw3gjZxSE%3d
re:
adalimumab biosimilars and supply of Humira as still pending response from
Pharmaceutical... and anifrolumab)
7.6 PBAC Meeting November agenda (adalimumab)
• The PBAC have released the Nov meeting agenda and the TC are invited to comment.
AbbVie have put in request for adalimumab and upadacitinib
https://rheumatology.org.au/LinkClick.aspx?fileticket=eYHw3gjZxSE%3d&portalid=2
, adalimumab, baricitinib, certolizumab, etanercept,
golimumab, infliximab, rituximab, tofacitinib, and upadacitinib) and for the treatment of severe
active juvenile idiopathic arthritis (adalimumab
https://rheumatology.org.au/LinkClick.aspx?fileticket=KYjdOWWUDw8%3d
.
Patient Case: An elderly patient had their adalimumab continued by the GP even though they
had
https://rheumatology.org.au/LinkClick.aspx?fileticket=%2flUCxoDSOhs%3d
(S100 Private) 14505
2
nd
or subsequent continuing RA adalimumab, baricitinib
https://rheumatology.org.au/LinkClick.aspx?fileticket=gMMZbMFrTLY%3d
to the board to reconsider the prescribing of
methotrexate by NP’s.
12.2 Adalimumab for uveitis...) and they are looking to make a submission to the
PBAC to get adalimumab on the PBS for uveitis
• Most patients with uveitis needing biologic treatment access adalimumab
through the AbbVie
https://rheumatology.org.au/LinkClick.aspx?fileticket=%2fxZA7E0in%2bE%3d
to the board to reconsider the prescribing of
methotrexate by NP’s.
12.2 Adalimumab for uveitis...) and they are looking to make a submission to the
PBAC to get adalimumab on the PBS for uveitis
• Most patients with uveitis needing biologic treatment access adalimumab
through the AbbVie
https://rheumatology.org.au/LinkClick.aspx?fileticket=FERFMjS2VpI%3d
, etanercept, rituximab
• Currently approved, not yet in market- adalimumab (more than one biosimilar brand)
• Infliximab, etanercept and adalimumab biosimilars have been deemed by the PBAC... this driver to also become available for biosimilar forms of adalimumab,
when they come to market
https://rheumatology.org.au/LinkClick.aspx?fileticket=s2uYhpyqu1M%3d